VMA, HVA, 5-HIAA in Urine - HPLC

Order No.: 1000/B, for 100 tests
Parameters:
5-Hydroxyindoleacetic Acid (5-HIAA), Homovanillic Acid (HVA), Vanillylmandelic Acid (VMA)

No pH-adjustment necessary
Two internal standards available
Suitable for automated sample preparation

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

5-Hydroxyindoleacetic Acid (5-HIAA)

Homovanillic Acid (HVA)

Vanillylmandelic Acid(VMA)

Clinical Relevance

Neuroblastoma is a neoplastic disease that is among the most common malignant cancers occurring during childhood. It is a neuroendocrine tumour resulting in higher excretion of the catecholamine metabolites vanillylmandelic acid (VMA) and homovanillic acid (HVA) in the urine. Therefore verification of these parameters is critical in the diagnosis of neuroblastoma.

In contrast, increased concentrations of hydroxyindoleacetic acid (5-HIAA) detected in the urine are an indication of a carcinoid tumour. The malignant reproduction of enterochromaffin cells in the gastrointestinal tract leads to increased production of the tissue hormone serotonin, whose primary metabolite is 5-HIAA. 

This assay allows the quantitative detection of vanillylmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in human urine samples via high performance liquid chromatography (HPLC) with electrochemical detection. The assay is used as a test for patients in whom the urine levels of these metabolites are of clinical importance.

 

Product advantages

• No pH-adjustment necessary
• Two internal standards available
• Automated sample preparation for Gilson® ASPEC™ is available

 

Assay characteristics

Prior to chromatographic separation, the analytes are separated from the urine matrix by ion exchange – Sample Clean Up columns ensure easy sample preparation.

Detailed performance evaluation data for this assay can be found in the appendices of the instruction manual.

More Information
Method of Analysis HPLC
Number of Tests 100
Please note The information listed here, including the sample preparation, is not sufficient for using the product. Please read the information provided in the instruction manual, which includes detailed information on limitations associated with the use of the product in line with its intended purpose. Detailed performance evaluation data for this assay can be found in the appendices of the instruction manual.
Lower and Upper Limit of Quantitation

VMA: 0.2 mg/l – 78 mg/l
HVA: 0.2 mg/l – 51 mg/l
5-HIAA: 0.2 mg/l – 76 mg/l

The LLOQ depends on the conditions of the working electrode.

Specimen 24 h urine; spontaneous urine (refer the data to urine creatinine)
Sample Preparation

The information on the sample preparation presented here is not sufficient for use in the laboratory. For a detailed step by step description, please refer to the instruction manual.

  • Extraction: Add 1 ml Internal Standard to 50 µl urine and mix. Apply entire sample to the sample clean up column, draw through by vacuum or centrifugation, discard effluent.
  • Washing: Apply 3 ml Wash Buffer I to the sample clean up column, discard effluent. Apply 2 times 3 ml Wash Buffer II, discard effluents.
  • Elution: Apply 2.0 ml Elution Buffer to the sample clean up column, collect eluate. Add 100 µl Finisher and mix briefly.
  • Inject 10–20 µl into the HPLC system.
Run Time approx. 20 min
Injection Volume 10-20 µl
Flow Rate 1 ml/min
Column Temperature ambient (~25 °C)
Potential approx. +700 mV to 850 mV
Additional Info For the HPLC analysis of VMA, HVA and 5-HIAA in urine any isocratic HPLC system with electrochemical detector is suitable.
Parameters 5-Hydroxyindoleacetic Acid (5-HIAA), Homovanillic Acid (HVA), Vanillylmandelic Acid (VMA)
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.

5-Hydroxyindoleacetic Acid (5-HIAA)

Homovanillic Acid (HVA)

Vanillylmandelic Acid(VMA)

Clinical Relevance

Neuroblastoma is a neoplastic disease that is among the most common malignant cancers occurring during childhood. It is a neuroendocrine tumour resulting in higher excretion of the catecholamine metabolites vanillylmandelic acid (VMA) and homovanillic acid (HVA) in the urine. Therefore verification of these parameters is critical in the diagnosis of neuroblastoma.

In contrast, increased concentrations of hydroxyindoleacetic acid (5-HIAA) detected in the urine are an indication of a carcinoid tumour. The malignant reproduction of enterochromaffin cells in the gastrointestinal tract leads to increased production of the tissue hormone serotonin, whose primary metabolite is 5-HIAA. 

This assay allows the quantitative detection of vanillylmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in human urine samples via high performance liquid chromatography (HPLC) with electrochemical detection. The assay is used as a test for patients in whom the urine levels of these metabolites are of clinical importance.

 

Product advantages

• No pH-adjustment necessary
• Two internal standards available
• Automated sample preparation for Gilson® ASPEC™ is available

 

Assay characteristics

Prior to chromatographic separation, the analytes are separated from the urine matrix by ion exchange – Sample Clean Up columns ensure easy sample preparation.

Detailed performance evaluation data for this assay can be found in the appendices of the instruction manual.

More Information
Method of Analysis HPLC
Number of Tests 100
Please note The information listed here, including the sample preparation, is not sufficient for using the product. Please read the information provided in the instruction manual, which includes detailed information on limitations associated with the use of the product in line with its intended purpose. Detailed performance evaluation data for this assay can be found in the appendices of the instruction manual.
Lower and Upper Limit of Quantitation

VMA: 0.2 mg/l – 78 mg/l
HVA: 0.2 mg/l – 51 mg/l
5-HIAA: 0.2 mg/l – 76 mg/l

The LLOQ depends on the conditions of the working electrode.

Specimen 24 h urine; spontaneous urine (refer the data to urine creatinine)
Sample Preparation

The information on the sample preparation presented here is not sufficient for use in the laboratory. For a detailed step by step description, please refer to the instruction manual.

  • Extraction: Add 1 ml Internal Standard to 50 µl urine and mix. Apply entire sample to the sample clean up column, draw through by vacuum or centrifugation, discard effluent.
  • Washing: Apply 3 ml Wash Buffer I to the sample clean up column, discard effluent. Apply 2 times 3 ml Wash Buffer II, discard effluents.
  • Elution: Apply 2.0 ml Elution Buffer to the sample clean up column, collect eluate. Add 100 µl Finisher and mix briefly.
  • Inject 10–20 µl into the HPLC system.
Run Time approx. 20 min
Injection Volume 10-20 µl
Flow Rate 1 ml/min
Column Temperature ambient (~25 °C)
Potential approx. +700 mV to 850 mV
Additional Info For the HPLC analysis of VMA, HVA and 5-HIAA in urine any isocratic HPLC system with electrochemical detector is suitable.
Parameters 5-Hydroxyindoleacetic Acid (5-HIAA), Homovanillic Acid (HVA), Vanillylmandelic Acid (VMA)
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.